Is Sanara MedTech, Inc. overvalued or undervalued?

As of 11 February 2019, the valuation grade for Sanara MedTech, Inc. moved from fair to risky, indicating a shift in perception regarding its investment potential. The company appears to be overvalued given its current financial metrics, including a Price to Book Value of 7.15, an EV to EBIT of -32.29, and an EV to EBITDA of -73.36, which reflect significant losses and negative earnings performance.
In comparison to its peers, Sanara MedTech's valuation ratios are concerning. For instance, CareDx, Inc. has a P/E ratio of -58.5934 and an EV to EBITDA of -71.7879, while AngioDynamics, Inc. shows a P/E of -21.8992 and an EV to EBITDA of 373.3922, both indicating a more favorable position relative to Sanara. Additionally, the company's recent stock performance has lagged behind the S&P 500, with a year-to-date return of -16.20% compared to the index's 2.44%. Overall, these factors suggest that Sanara MedTech is overvalued in its current state.